Candel Therapeutics To Present Data From Its Phase 2 Clinical Trial Of CAN-2409 At ASCO
Candel Therapeutics To Present Data From Its Phase 2 Clinical Trial Of CAN-2409 At ASCO
Candel Therapeutics 将在 ASCO 公布其 CAN-2409 二期临床试验的数据
As of the data cut-off date, CAN-2409 treatment in NSCLC continued to exhibit a favorable safety and tolerability profile
截至数据截止日期,NSCLC 的 CAN-2409 治疗继续表现出良好的安全性和耐受性
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。